| Project Number | pCODR 10162 |
|---|---|
| Brand Name | Venclexta in combo Rituximab |
| Generic Name | Venetoclax |
| Tumour Type | Leukemia |
| Indication | Chronic Lymphocytic Leukemia (CLL) |
| Funding Request | In combination with rituximab (V+R) is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy |
| Review Status | Under Review |
| Pre Noc Submission | No |
| NOC Date | September 21, 2018 |
| Manufacturer | AbbVie Corporation |
| Submitter | AbbVie Corporation |
| Submission Date | October 24, 2018 |
| Submission Deemed Complete | November 7, 2018 |
| Submission Type | New Indication |
| Prioritization Requested | |
| Stakeholder Input Deadline ‡ | November 7, 2018 |
| Check-point meeting | January 8, 2019 |
| pERC Meeting (target date) | March 21, 2019 |
| Initial Recommendation Issued (target date) | April 4, 2019 |
| Feedback Deadline (target date) ‡ | |
| pERC Reconsideration Meeting (target date) | |
| Final Recommendation Issued (target date) | |
| Notification to Implement Issued |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.